Article

Improved form of brimonidine has fewer contraindications

Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.

Related Videos
2 experts are featured in this series.
Related Content
Ophthalmology Times 2024 wrap-up: A year of innovation and insight
December 26th 2024

Ophthalmology Times 2024 wrap-up: A year of innovation and insight

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Targeting IL-6 inflammation: A promising frontier in treating thyroid eye disease
December 26th 2024

Targeting IL-6 inflammation: A promising frontier in treating thyroid eye disease

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Exploring electrical stimulation therapy: A promising approach to vision loss in optic neuropathies
Published: December 26th 2024 | Updated: December 26th 2024

Exploring electrical stimulation therapy: A promising approach to vision loss in optic neuropathies

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery
Published: December 26th 2024 | Updated: December 26th 2024

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery

© 2024 MJH Life Sciences

All rights reserved.